FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1373-1377 May 3, 2001 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Editorial by Lee, T. H. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

A 65-year-old man with no risk factors for prostate cancer except his age has a normal digital rectal examination. Should a prostate-specific–antigen (PSA) test be ordered?

The Clinical Problem

The introduction of PSA testing in 1987 resulted in an enormous increase in the reported incidence of prostate cancer in the United States. After peaking in 1992, the incidence fell, presumably owing to the identification of . . . [Full Text of this Article]

The PSA Test

Tests That May Improve the Performance of the PSA Test

Screening Interval

Strategies and Evidence

Areas of Uncertainty

Guidelines

Conclusions and Recommendations

Source Information

From the Medical Practices Evaluation Center, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School — both in Boston.

Address reprint requests to Dr. Barry at the Medical Practices Evaluation Center, Massachusetts General Hospital, 50 Staniford St., 9th Fl., Boston, MA 02114.

References

This article has been cited by other articles:

• Chapple, A., Ziebland, S., Hewitson, P., McPherson, A. (2008). Why Men in the United Kingdom Still Want the Prostate Specific Antigen Test. Qual Health Res 18: 56-64 [Abstract]  
• Casiano, C. A., Mediavilla-Varela, M., Tan, E. M. (2006). Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer. Mol. Cell. Proteomics 5: 1745-1759 [Abstract] [Full Text]  
• Taylor, L. S., Rubens, D. J., Porter, B. C., Wu, Z., Baggs, R. B., di Sant'Agnese, P. A., Nadasdy, G., Pasternack, D., Messing, E. M., Nigwekar, P., Parker, K. J. (2005). Prostate Cancer: Three-dimensional Sonoelastography for in Vitro Detection. Radiology 237: 981-985 [Abstract] [Full Text]  
• Rubin, M. A., Bismar, T. A., Andren, O., Mucci, L., Kim, R., Shen, R., Ghosh, D., Wei, J. T., Chinnaiyan, A. M., Adami, H.-O., Kantoff, P. W., Johansson, J.-E. (2005). Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death. Cancer Epidemiol. Biomarkers Prev. 14: 1424-1432 [Abstract] [Full Text]  
• Ford, M. E., Havstad, S. L., Demers, R., Cole Johnson, C. (2005). Effects of False-Positive Prostate Cancer Screening Results on Subsequent Prostate Cancer Screening Behavior. Cancer Epidemiol. Biomarkers Prev. 14: 190-194 [Abstract] [Full Text]  
• Beatty, P. A., Glaser, A. I., Rocco, B., Matei, D. V., de Cobelli, O., Datta, M. W., Berman, J. J., Dhir, R. (2004). Prostate Cancer with Low PSA Levels. NEJM 351: 1802-1803 [Full Text]  
• Shabbir, M., Mumtaz, F. H (2004). Benign prostatic hyperplasia. The Journal of the Royal Society for the Promotion of Health 124: 222-227 [Abstract]  
• Tsao, A. S., Kim, E. S., Hong, W. K. (2004). Chemoprevention of Cancer. CA Cancer J Clin 54: 150-180 [Abstract] [Full Text]  
• Law, M. (2004). Screening without evidence of efficacy. BMJ 328: 301-302 [Full Text]  
• Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., Reuter, V., Gerald, W. L. (2004). Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance. Am. J. Pathol. 164: 217-227 [Abstract] [Full Text]  
• Nakamura, T., Scorilas, A., Stephan, C., Jung, K., Soosaipillai, A. R., Diamandis, E. P. (2003). The Usefulness of Serum Human Kallikrein 11 for Discriminating between Prostate Cancer and Benign Prostatic Hyperplasia. Cancer Res. 63: 6543-6546 [Abstract] [Full Text]  
• Cramer, S. D., Chang, B.-L., Rao, A., Hawkins, G. A., Zheng, S. L., Wade, W. N., Cooke, R. T., Thomas, L. N., Bleecker, E. R., Catalona, W. J., Sterling, D. A., Meyers, D. A., Ohar, J., Xu, J. (2003). Association Between Genetic Polymorphisms in the Prostate-Specific Antigen Gene Promoter and Serum Prostate-Specific Antigen Levels. JNCI J Natl Cancer Inst 95: 1044-1053 [Abstract] [Full Text]  
• Gao, C.-L., Rawal, S. K., Sun, L., Ali, A., Connelly, R. R., Banez, L. L., Sesterhenn, I. A., Mcleod, D. G., Moul, J. W., Srivastava, S. (2003). Diagnostic Potential of Prostate-specific Antigen Expressing Epithelial Cells in Blood of Prostate Cancer Patients. Clin. Cancer Res. 9: 2545-2550 [Abstract] [Full Text]  
• Yousef, G. M., Polymeris, M.-E., Yacoub, G. M., Scorilas, A., Soosaipillai, A., Popalis, C., Fracchioli, S., Katsaros, D., Diamandis, E. P. (2003). Parallel Overexpression of Seven Kallikrein Genes in Ovarian Cancer. Cancer Res. 63: 2223-2227 [Abstract] [Full Text]  
• Hoffman, R. M. (2003). An Argument Against Routine Prostate Cancer Screening. Arch Intern Med 163: 663-665 [Full Text]  
• Oottamasathien, S., Crawford, E. D. (2003). Rebuttal by Drs Oottamasathien and Crawford. Arch Intern Med 163: 665-666 [Full Text]  
• Diamandis, E. P., Scorilas, A., Fracchioli, S., van Gramberen, M., de Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G. M., Stenman, U.-H., Massobrio, M., van der Zee, A. G., Vergote, I., Katsaros, D. (2003). Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. JCO 21: 1035-1043 [Abstract] [Full Text]  
• Kishi, T., Grass, L., Soosaipillai, A., Shimizu-Okabe, C., Diamandis, E. P. (2003). Human Kallikrein 8: Immunoassay Development and Identification in Tissue Extracts and Biological Fluids. Clin. Chem. 49: 87-96 [Abstract] [Full Text]  
• Berlin, L. (2002). Liability for Failure to Order Screening Examinations. Am. J. Roentgenol. 179: 1401-1405 [Full Text]  
• Chapple, A., Ziebland, S., Shepperd, S., Miller, R., Herxheimer, A., McPherson, A. (2002). Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study. BMJ 325: 737-737 [Abstract] [Full Text]  
• Steineck, G., Helgesen, F., Adolfsson, J., Dickman, P. W., Johansson, J.-E., Norlen, B. J., Holmberg, L., the Scandinavian Prostatic Cancer Group Study Numb, (2002). Quality of Life after Radical Prostatectomy or Watchful Waiting. NEJM 347: 790-796 [Abstract] [Full Text]  
• Schwartz, L. M., Woloshin, S., Baczek, L. (2002). Media Coverage of Scientific Meetings: Too Much, Too Soon?. JAMA 287: 2859-2863 [Abstract] [Full Text]